Multicentre, Randomized, Multi-arm Trial Comparing the Efficacy and Safety of Adalimumab, Anakinra and Tocilizumab in Subjects With Non-infectious Refractory Uveitis RUBI: Refractory Uveitis BIotherapies
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Anakinra (Primary) ; Tocilizumab (Primary) ; Adalimumab
- Indications Uveitis
- Focus Therapeutic Use
- Acronyms RUBI
- 04 Jul 2017 Status changed from not yet recruiting to recruiting.
- 09 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.
- 13 Apr 2017 Planned initiation date changed from 1 Oct 2016 to 1 Apr 2017.